Advertisement

Detection of Influenza in the Epidemic Season 2016/2017 Based on I–MOVE+ Project

  • E. Hallmann-Szelińska
  • K. Cieślak
  • K. Szymański
  • D. Kowalczyk
  • M.  R. Korczyńska
  • I. Paradowska-Stankiewicz
  • L. B. Brydak
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1114)

Abstract

In the influenza season 2016/2017 in Europe, the predominant virus was A/H3N2/. In Poland, the percentage of people vaccinated against influenza was 3.33%. European I–MOVE+ project shows how important it is to monitor the effectiveness of influenza vaccine. The project demonstrates that a match between the circulating vaccine strains and those included in the vaccine for the Northern Hemisphere was low-to-moderate. In the present study, there were 379 patients and 296 control subjects examined in hospitals in Poland as part of I–MOVE+ project. The real-time reverse transcription polymerase chain reaction (qRT-PCR) method was used to detect the influenza virus in all subjects. We detected the influenza subtype A/H3N2/ in 59.1% and type B virus in 2.1%. There was one co–infection of subtype A/H3N2/ with subtype A/H1N1/ and eight co–infections of type B with subtype A/H3N2/. No influenza viruses were detected in the control group. Only 19 patients and 22 control subjects were vaccinated during the epidemic season in question. A proportion of people vaccinated against influenza in Poland remains dismally low compared to other European countries.

Keywords

Epidemic season Influenza Laboratory testing Subtype Vaccine 

Notes

Acknowledgments

This work was funded by grant 634446 within the project: “I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly – I-MOVE-plus”. Additionally, funded in part by the NIPH-NIH theme 3/EM. We would like to acknowledge physicians and employees of the Voivodship Sanitary Epidemiological Stations in Poland who participated in this program.

Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.

References

  1. ECDC (2017) European centre for disease prevention and control. https://sites.google.com/site/epiflu/. Accessed 26 Apr 2018
  2. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB (2017) Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2017–18 influenza season. MMWR Recomm Rep 66(2):1–20CrossRefPubMedPubMedCentralGoogle Scholar
  3. Hallmann-Szelińska E, Bednarska K, Korczyńska MR, Paradowska-Stankiewicz I, Brydak LB (2016) Virological characteristics of the 2014/2015 influenza season based on molecular analysis of biological material derived from I-MOVE study. Adv Exp Med Biol 921:81–85CrossRefGoogle Scholar
  4. Kissling E, Valenciano M, I-MOVE Case-Control Studies Team (2012) Early estimates of sesonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill 17(15):pii:20146Google Scholar
  5. Kissling E, Rondy M, I-MOVE/I-MOVE+ study team (2017) Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill 22(7):pii:30464CrossRefGoogle Scholar
  6. Paradowska-Stankiewicz I, Korczyńska MR, Cieślak K, Kowalczyk D, Szymański K, Brydak LB (2018) Vaccine effectiveness against influenza in 2015/16 in hospital and ambulatory medical care facilities: polish results of the European I-MOVE+ multicenter study. Adv Exp Med Biol 1023:93–100CrossRefPubMedGoogle Scholar
  7. Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F, I-MOVE Multicentre Case Control Study Team (2015) The European I-MOVE multicentre 2013–2014 case-control study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogeneous results by country against A(H3N2). Vaccine 33(24):2813–2822CrossRefPubMedGoogle Scholar
  8. Weinberg GA, Szilagyi PG (2010) Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201:1607–1610CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • E. Hallmann-Szelińska
    • 1
  • K. Cieślak
    • 1
  • K. Szymański
    • 1
  • D. Kowalczyk
    • 1
  • M.  R. Korczyńska
    • 2
  • I. Paradowska-Stankiewicz
    • 2
  • L. B. Brydak
    • 1
  1. 1.Department of Influenza Research, National Influenza CenterNational Institute of Public Health – National Institute of HygieneWarsawPoland
  2. 2.Department of EpidemiologyNational Institute of Public Health – National Institute of HygieneWarsawPoland

Personalised recommendations